<h1>Affordable biosimilar access expands treatment availability for HER2-positive breast cancer through a new domestic Pertuzumab alternative.</h1> The launch of Perzea, an affordable Pertuzumab biosimilar by Hetero Healthcare with Enzene Biosciences, is described as expanding access to HER2 positive breast cancer treatment by lowering cost barriers. The partnership and Enzene's EnzeneXTM manufacturing technology are presented as the enabling mechanisms for increased domestic biologics production and affordability, framed within national objectives of equitable healthcare access.